GLP-1受体激动剂和下一代代代谢激素疗法在慢性脏疾病中
Radica Z Alicic1,2, Joshua J Neumiller1,3, Katherine R Tuttle4,5,6
1Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA, USA.
Nature reviews. Nephrology
|January 8, 2026
概括
类似葡萄糖-1受体激动剂 (GLP-1RAs) 对心血管--代谢综合征提供了显著的益处. 这些疗法不仅可以改善代谢健康,还可以通过非代谢途径保护心脏和脏.
科学领域:
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
背景情况:
- 慢性病 (CKD),2型糖尿病和肥胖是全球主要的健康问题.
- 心血管--代谢 (CKM) 综合征将这些疾病联系在一起,这是由于共同的病理生理学和代谢风险因素.
- 降血糖疗法的出现已经改变了CKM综合征的管理.
研究的目的:
- 探索基于隐形素的疗法,特别是GLP-1受体激活剂 (GLP-1RAs) 在管理CKM综合征中的不断变化的作用.
- 突出GLP-1RAs除了其代谢作用之外的心血管和脏保护作用.
- 调查基于烯的疗法的非代谢益处的机制.
主要方法:
- 关于基于隐素的治疗方法的当前文献的审查,重点关注GLP-1RAs和相关药物.
- 对临床试验数据的分析,证明GLP-1RAs对代谢,心血管,脏和死亡率的影响.
- 检查临床前和临床证据,以检查因克莱在炎症和纤维化通路上的系统和局部作用.
主要成果:
- 最初用于降低葡萄糖的GLP-1RAs,在CKM综合征中显示出显著的益处.
- 这些药物可以减少高血糖,体重,以及不同人群中主要的脏,心血管和死亡结果.
- 心脏保护和脏保护作用超出了代谢改善的范围,表明对炎症和纤维化通路的调节.
结论:
- GLP-1RAs代表了CKM综合征治疗的范式转变,提供了代谢和器官保护的好处.
- 非代谢作用,包括抗炎和抗纤维作用,对于观察到的脏和心脏保护至关重要.
- 对因克雷丁和代谢激素作用的进一步研究是有必要的,以充分阐明CKM综合征的病理生理学和治疗.
相关概念视频
01:24Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
01:28Chronic Kidney Disease III: Interprofessional Care
333
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
333
01:06Oral Hypoglycemic Agents: Glinides
593
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
593
01:23Dipeptidyl Peptidase 4 Inhibitors
575
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K